Haloperidol

Haloperidol is an antipsychotic drug that acts as a dopamine antagonist. It is used to treat Tourette’s Disorder, schizophrenia and other psychotic conditions, and the symptoms associated with chemotherapy. It can be administered by the oral route or by injection.

Haloperidol passed the animal data screen, underwent a preliminary toxicological evaluation, and is being brought to the Carcinogen Identification Committee for consultation. This is a compilation of the relevant studies identified during the preliminary toxicological evaluation.

Epidemiological data

No cancer epidemiology studies were identified.

Animal carcinogenicity data

- Intraperitoneal injection studies in mice
  - Male NMRI mice, daily injections for five, 10, or 20 consecutive days and observed for up to 16 months: Fey et al. (1982)
  - Male and female AKC3F1 hybrid mice, weekly injections for seven weeks and observed for eight months: Ember et al. (1985)
  - Male and female mice of different strains—NMRI, AKR, XVII AKF1 hybrid, and male BALB/c/BOM mice, daily injections for five days and observed for seven to 24 months, depending on strain: Wunderlich et al. (1987)
  - Male Swiss mice, daily injections for five, 10, or 20 consecutive days and observed for 18 months: Van Cauteren et al. (1987)

- Long-term oral administration in mice

- Long-term oral administration in rats
  - 24-month studies in male and female Wistar rats: PDR (2005)

- Co-administration studies in mice
  - AKR mice, single subcutaneous injection of nitrosomethylurea on day 1 and i.p. injection of haloperidol on days 3-5, and observed for seven months: Wunderlich et al. (1987)
  - AKR mice, daily i.p. injection of haloperidol for five days, followed by twice weekly i.p. injections of 12-O-tetradecanoylphorbol-13-acetate (TPA) for five weeks, and observed for seven months: Wunderlich et al. (1987)
Other relevant data

- Genotoxicity
  - chromosome aberration and sister chromatid exchange test in CHO cells *in vitro*: reviewed in CCRIS (2006)

References¹


¹ Copies of these listed references, as either the abstract, the relevant sections of the publication, or the complete publication, have been provided to members of the Carcinogen Identification Committee. These references have been provided in the order in which they are discussed in this document.